RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Risk Management of New DMTs
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 2
SP 18
OP 19
DO 10.1177/155989771202013
UL http://mdc.sagepub.com/content/12/2/18.abstract
AB DMTs for multiple sclerosis (MS) carry potentially serious risks, including opportunistic infections, altered response to vaccinations, development of cancer, and the appearance of autoimmune disorders. This article reviews safety data from clinical studies and post-marketing surveillance of DMTs for MS, as well as discusses the risks associated with such new therapies.